MP14-14 CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND CLINICAL OUTCOME IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH NIVOLUMAB: A REAL-WORLD MULTI-INSTITUTIONAL RETROSPECTIVE STUDY

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Sep 2021MP14-14 CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND CLINICAL OUTCOME IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH NIVOLUMAB: A REAL-WORLD MULTI-INSTITUTIONAL RETROSPECTIVE STUDY Taigo Kato, Akira Nagahara, Norihiko Kawamura, Wataru Nakata, Tetsuji Soda, Kyosuke Matsuzaki, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Kensaku Nishimura, Shingo Takada, Masao Tsujihata, Seiji Yamaguchi, Tetsuya Takao, Kazuo Nishimura, Motohide Uemura, and Norio Nonomura Taigo KatoTaigo Kato More articles by this author , Akira NagaharaAkira Nagahara More articles by this author , Norihiko KawamuraNorihiko Kawamura More articles by this author , Wataru NakataWataru Nakata More articles by this author , Tetsuji SodaTetsuji Soda More articles by this author , Kyosuke MatsuzakiKyosuke Matsuzaki More articles by this author , Koji HatanoKoji Hatano More articles by this author , Atsunari KawashimaAtsunari Kawashima More articles by this author , Takeshi UjikeTakeshi Ujike More articles by this author , Kensaku NishimuraKensaku Nishimura More articles by this author , Shingo TakadaShingo Takada More articles by this author , Masao TsujihataMasao Tsujihata More articles by this author , Seiji YamaguchiSeiji Yamaguchi More articles by this author , Tetsuya TakaoTetsuya Takao More articles by this author , Kazuo NishimuraKazuo Nishimura More articles by this author , Motohide UemuraMotohide Uemura More articles by this author , and Norio NonomuraNorio Nonomura More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001995.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) such as anti-programmed cell death protein-1 (PD-1) antibody have become the most attractive treatment in cancer field. Recent studies have shown that immune-related adverse events (irAEs) caused by ICIs were correlated with favorable clinical outcome in patients with melanoma. However, in metastatic renal cell carcinoma (mRCC) patients, there have been few reports about the correlation between irAEs and clinical efficacy of anti- PD-1 therapy. METHODS: We retrospectively investigated 160 mRCC patients who started nivolumab monotherapy between September 2016 and July 2019. IrAEs were defined as patients’ AEs having a potential immunological basis that required close follow-up, or immunosuppressive therapy. We aimed to report the real-world efficacy and toxicity of nivolumab in patients with mRCC and particularly focused on the correlation between irAEs and clinical outcome in mRCC patients treated with nivolumab. RESULTS: Of all mRCC patients, 47 patients (29.4%) developed irAEs. In patients who developed irAEs, the objective response rate and disease control rate were 38.8% and 77.6%, which were significantly higher when compared to that in patients without irAEs (p = 0.012 and p < 0.001, respectively). Furthermore, the incidence of irAEs were significantly associated with an increase in progression-free survival (PFS) (HR=0.4867; p=0.0006) and overall survival (OS) (HR=0.526; p=0.0252) (Figure 1A). Importantly, PFS and OS seemed to be similar in patients who discontinued treatment because of irAEs and in those who did not discontinue because of irAEs (p = 0.36 and p = 0.35, respectively, Figure 1B). CONCLUSIONS: To our knowledge, we first showed that patients who discontinued nivolumab because of irAEs has similar clinical outcome with those who did not discontinued nivolumab after irAEs in mRCC. In a real-world setting, this study also validated the correlation between irAEs and anti-PD-1 efficacy in mRCC patients treated with nivolumab. Source of Funding: Not available © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e258-e258 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Taigo Kato More articles by this author Akira Nagahara More articles by this author Norihiko Kawamura More articles by this author Wataru Nakata More articles by this author Tetsuji Soda More articles by this author Kyosuke Matsuzaki More articles by this author Koji Hatano More articles by this author Atsunari Kawashima More articles by this author Takeshi Ujike More articles by this author Kensaku Nishimura More articles by this author Shingo Takada More articles by this author Masao Tsujihata More articles by this author Seiji Yamaguchi More articles by this author Tetsuya Takao More articles by this author Kazuo Nishimura More articles by this author Motohide Uemura More articles by this author Norio Nonomura More articles by this author Expand All Advertisement Loading ...